<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141298">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966783</url>
  </required_header>
  <id_info>
    <org_study_id>BUS-2/UCA</org_study_id>
    <secondary_id>2012-003362-41</secondary_id>
    <nct_id>NCT01966783</nct_id>
  </id_info>
  <brief_title>Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis</brief_title>
  <official_title>Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of budesonide
      suppository for the treatment of acute ulcerative proctitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Resolution of clinical symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms as reported in the diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical and endoscopic remission</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms as reported in the diary, ulcerative colitis-disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of improvement</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms as reported in the diary, ulcerative colitis-disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with clinical remission</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms as reported in the diary, ulcerative colitis-disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with endoscopic remission</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ulcerative colitis-disease activity index</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Proctitis</condition>
  <arm_group>
    <arm_group_label>Budesonide dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide 2 mg suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide 4 mg suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesalazine 1g suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide 2 mg suppository/Mesalazine 1 g suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 2 mg suppository</intervention_name>
    <description>per day</description>
    <arm_group_label>Budesonide dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 4 mg suppository</intervention_name>
    <description>per day</description>
    <arm_group_label>Budesonide dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine 1 g suppository</intervention_name>
    <description>per day</description>
    <arm_group_label>Mesalazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 2 mg suppository/Mesalazine 1 g suppository</intervention_name>
    <description>per day</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active ulcerative proctitis

          -  Diagnosis confirmed by endoscopy

          -  Established disease or new diagnosis

        Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,
             diverticular assoc. colitis, microscopic colitis

          -  Presence of proctitis of a different origin

          -  Prior bowel resection

          -  Presence of symptomatic organic disease of the gastrointestinal tract

          -  Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active
             peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is
             not ensured

          -  Local intestinal infection

          -  Abnormal hepatic or renal function

          -  Oral/rectal/intravenous corticosteroids therapy

          -  Existing or intended pregnancy or breast-feeding

          -  Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Kruis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evang. Krankenhaus Kalk, Medical Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Britta Siegmund, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité-Campus Benjamin Franklin Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Mohrbacher, MSc</last_name>
    <phone>++49-761-1514-0</phone>
    <phone_ext>156</phone_ext>
    <email>mohrbacher@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Greinwald, PhD</last_name>
    <phone>++49-761-1514-0</phone>
    <phone_ext>0</phone_ext>
    <email>greinwald@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité-Campus Benjamin Franklin Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Siegmund, Professor</last_name>
      <phone>++40 30 450514</phone>
      <phone_ext>322</phone_ext>
      <email>britta.siegmund@charite.de</email>
    </contact>
    <investigator>
      <last_name>Britta Siegmund, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evang. Krankenhaus Kalk, Medical Department</name>
      <address>
        <city>Cologne</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Kruis, Professor</last_name>
      <phone>++49 221 8289</phone>
      <phone_ext>5289</phone_ext>
      <email>kruis@evkk.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Kruis, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proctitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
